企業プロフィール
Alvotech 株価・ニュース・カタリスト
- ティッカー:
- ALVO
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- Iceland
株価パフォーマンス
5.62 USD (-3.10%)
終値
最終更新: 2026年10月1日
936M USD
時価総額
株価変動の要因
最新のモニタリング対象企業ニュースは「Matvæla- og lyfjastofnun Bandaríkjanna (FDA) veitir viðbótarleyfi fyrir framleiðslu á hliðstæðunni við Humira í báðum framleiðslueiningum lyfjaverksmiðju Alvotech í Reykjavík」です。対応する終値の反応はまだ確認できません。
企業概要
Global Biosimilar Developer and Manufacturer
Alvotech is a biotechnology company focused exclusively on developing and manufacturing biosimilar medicines. It operates an integrated model covering cell-line development, process development, clinical studies, regulatory submissions, commercial-scale manufacturing, and supply to regional marketing partners.
Commercial Biosimilar Portfolio
The marketed portfolio includes biosimilars referencing Humira and Stelara, providing exposure to large immunology markets. Additional products referencing Prolia/Xgeva, Simponi/Simponi Aria, and Eylea broaden the portfolio into bone disease and ophthalmology.
Global Partnership Model
Alvotech generally partners with regional pharmaceutical companies for commercialization while retaining responsibility for development and manufacturing. This structure gives the company access to many markets without building a fully owned sales organization in every country.
Manufacturing-Centered Strategy
Complex biologic manufacturing is a core competitive capability. Alvotech's facilities support development through commercial supply, and regulatory inspections, manufacturing readiness, and reliable scale-up are critical to both product approvals and partner launches.
Expanding Late-Stage Pipeline
The pipeline includes AVT03, AVT05, AVT06, AVT16, AVT80, and additional biosimilars targeting high-value biologics across immunology, ophthalmology, oncology, and other specialty markets. Multiple candidates are being reviewed across the United States, Europe, and additional international jurisdictions.
今後のカタリスト
- FDA regulatory decisions in the fourth quarter of 2026 for resubmitted applications covering AVT03, AVT05, and AVT06.
- Regulatory decisions for additional late-stage biosimilars AVT16 and AVT80 following ongoing U.S. and European reviews.
最近のニュース
ニュースタイトルは機械翻訳です。詳細は英語の原文をご覧ください。
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。